SharesGrow.com 标普和纳斯达克内在价值联系我们

हिन्दी

← 返回所有股票

BioAtla, Inc. BCAB NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

BioAtla, Inc. (BCAB) 有 12 个已识别的同行可供比较在 Healthcare 板块. 同行包括 ACRV, ADAG, ANTX, AVTE, CCCC, DSGN 等.

BCAB 的市值为 $4.94M, 而同行平均市值为 $788.06M. BCAB 显著小于其平均同行.

同行与相似公司 — BCAB

Acrivon Therapeutics, Inc. Common Stock

$1.64 +1.86% $51.75M

$3.81 -0.78% $143.44M

AN2 Therapeutics, Inc.

$2.98 -1.00% $81.66M

Aerovate Therapeutics, Inc.

$2.68 0.00% $77.68M

C4 Therapeutics, Inc.

$2.76 +0.91% $228.6M

Design Therapeutics, Inc.

$12.64 +2.35% $779.54M

$17.85 +9.44% $5.55B

Foghorn Therapeutics Inc.

$4.85 +3.41% $284.7M

Monte Rosa Therapeutics, Inc.

$17.50 -0.28% $1.14B

Gracell Biotechnologies Inc.

$10.25 +0.05% $197.97M

Ikena Oncology, Inc.

$17.16 +1,152.55% $718.82M

Century Therapeutics, Inc.

$2.37 +4.41% $205.17M

其他人也在看

Kymera Therapeutics, Inc.

Olema Pharmaceuticals, Inc.

Nurix Therapeutics, Inc.

Monte Rosa Therapeutics, Inc.

Design Therapeutics, Inc.

Ikena Oncology, Inc.

Nautilus Biotechnology, Inc.

联系我们

🎓

SharesGrow 学院

学习如何计算内在价值，发现被低估的股票。

每周在线课程

📧 [email protected]

📞 +65 8912 8000

给我们留言